AdvanSource Biomaterials Obtains US Patent for Antimicrobial Polyurethane Resins

A range of antimicrobial polyurethane resins developed by AdvanSource Biomaterials is effective against MRSA, pictured here in a scanning electron micrograph.

AdvanSource Biomaterials Corp., a developer of polymer technologies and materials for various medical device applications, has announced that it has received a “Notice of Allowance” from the US Patent and Trademark Office in connection with its antimicrobial patent application filed in June 2007. US Patent No. 7,772,296, which is entitled “Antimicrobial Polyurethane Resins and Products Made Therefrom,” covers a drug-free, antimicrobial technology to eradicate Methicillin-resistant Staphylococcus aureus (MRSA) clinical infections associated with medical devices.

The company believes that infection rates from MRSA, primarily from hospitals and other medical facilities, pose significant risks to patient populations and are increasing in frequency.

The firm’s proprietary manufacturing process is differentiated by an innovative methodology whereby an antimicrobial agent is incorporated during the synthesis of a resin, using its advanced polymer technologies, which is suitable for molding into medical devices. These antimicrobial formulations are designed to possess a high degree of bacterial “kill.” The resultant antimicrobial polymers may then be used as structural components or as coatings in various catheters, including venus, arterial and urological.

“This patent underscores the strength of our technology team and their capabilities in developing innovative technologies to meet clear market needs,” says Michael Adams, AdvanSource’s President and Chief Executive Officer. ”There have been many studies and well-documented evidence in support of the risks associated with infection from invasive and minimally invasive medical devices, such as catheters. We believe our antimicrobial polymers could now provide medical device developers and manufacturers with a biomaterial choice providing them a competitive advantage in the marketing and sales of medical devices which are constructed or coated with our patented antimicrobial polymers. We are gratified in being able to add this important technology innovation to our growing portfolio of patents.”

Tags: AdvanSource Biomaterials, Antimicrobial, methicillin-resistant staphylococcus aureus, MRSA, US Patent and Trademark Office